1. Scrip
  2. >>R&D
  3. >>Clinical Trials

GeNeuro, Servier 'Disappointed' With Mid-Way Phase IIb Multiple Sclerosis Study

 
• By Sten Stovall

GeNeuro and partner Servier voiced disappointment over results seen midway through a Phase IIb trial studying a potential cause of multiple sclerosis - but insisted the trial will continue for the final 6 months.

Human brain
GeNeuro "Disappointed" With Mid-Way Results For CHANGE-MS Phase IIb Study • Source: Shutterstock

Voicing clear disappointment, GeNeuro SA said there is no difference at six-months between active- and placebo-treated subjects in its mid-stage CHANGE-MS trial testing the Swiss group's lead candidate GNbAC1 in treating with relapsing-remitting multiple sclerosis (RRMS).

But desipte being "disappointed", GeNeuro and its French partner Servier SA, said they will persevere until the study's 12-month...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Nanobiotix/J&J Early Melanoma Data Show Potential For Future Indication

 
• By Mandy Jackson

Radiotherapy enhancer JNJ-1900 (NBTXR3) generated a 47% ORR and 78.9% DCR in melanoma patients after multiple prior rounds of treatment. Discussions about development in additional cancers are ongoing with partner J&J.

EADV: Leo Makes A Big Leap With Eczema Drug Temtokibart Set For Phase III

 
• By Kevin Grogan

CSO Jacob Thyssen tells Scrip that the monoclonal antibody which blocks the IL-22RA1 receptor subunit is a very safe and effective option to treat the chronic inflammatory skin disease.

Incyte’s Povorcitinib Wins Stack Up, Will It Be Enough To Hedge Jakafi Loss?

 
• By Aakash Babu

With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.

Regeneron’s Garetosmab May Become Second Drug For Rare Bone Disease FOP

 
• By Alaric DeArment

The company announced positive Phase III data for the drug in fibrodysplasia ossificans progressiva, as well as Phase II combination data among patients with obesity.

More from R&D

Regeneron’s Garetosmab May Become Second Drug For Rare Bone Disease FOP

 
• By Alaric DeArment

The company announced positive Phase III data for the drug in fibrodysplasia ossificans progressiva, as well as Phase II combination data among patients with obesity.

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.

AstraZeneca’s Fasenra RESOLUTE Failure Highlights The Limits Of Biologics In COPD

 
• By Alexandra Shimmings

AstraZeneca’s IL-5 blocker has again missed in COPD, adding to a number of disappointments for biologics in this disease. Complex biology and overlapping inflammatory pathways seem to be at the heart of the problem.